High time for low-dose prospective clinical trials

✍ Scribed by Robert S. DiPaola; Henry J. Durivage; Barton A. Kamen

• Publisher: John Wiley and Sons
• Year: 2003
• Tongue: English
• Weight: 49 KB
• Volume: 98
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/cncr.11709

✦ Synopsis

The article by Glode et al. in this issue reports on the empiric success, as defined by a decreased prostate specific antigen level and lack of toxicity, of metronomically delivered low‐dose chemotherapy for patients with hormone‐refractory prostate carcinoma. The data presented were collected as a retrospective evaluation of the medical records of patients treated with cyclophosphamide and dexamethasone who were unable to participate in Phase II drug trials or had failed previous chemotherapy regimens.